Literature DB >> 8799686

Prevention and treatment of venous thromboembolism.

G F Pineo1, R D Hull.   

Abstract

All patients at moderate to high risk for the development of venous thromboembolism should receive prophylaxis. The approaches of proven value include low dose heparin, low molecular weight heparin, oral anticoagulants and intermittent pneumatic compression. The use of one of the cited heparin nomograms will ensure that all patients are rapidly brought within the therapeutic range. Because of the varying sensitivities of thromboplastins, each laboratory should establish a therapeutic range using the activated partial thromboplastin time (APTT) which will correspond to 0.2 to 0.4 U/ml of heparin. Constant vigilance and a high level of suspicion are necessary to establish the clinical diagnosis of heparin-induced thrombocytopenia, and to institute appropriate therapy. Physicians should be aware of the sensitivity of the thromboplastin being used in the performance of the International Normalised Ratio (INR). Care must be taken to ensure that patients are maintained within the target therapeutic range for INR (in most cases 2 to 3) by frequent determination of the INR and appropriate adjustments of warfarin dosage. Low molecular weight heparin is the recommended approach to the initial management of venous thromboembolism where these agents are available. Patients with an acute episode of venous thromboembolism should receive warfarin therapy for at least 3 months. At the present time it is reasonable to treat the first recurrence with oral anticoagulants for a period of 12 months and indefinitely for more than 1 recurrence. For selected patients with acute massive pulmonary embolism, thrombolytic therapy with one of the available agents is recommended. However, the role of thrombolytic therapy in patients with proximal venous thrombosis remains unclear. In selected patients with acute venous thromboembolism who have contraindications to anticoagulant therapy or who-have objectively documented recurrent disease while on adequate therapy, the insertion of an inferior vena cava filter is recommended.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799686     DOI: 10.2165/00003495-199652010-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  157 in total

1.  Intermittent pneumatic compression versus coumadin. Prevention of deep vein thrombosis in lower-extremity total joint arthroplasty.

Authors:  F A Kaempffe; R M Lifeso; C Meinking
Journal:  Clin Orthop Relat Res       Date:  1991-08       Impact factor: 4.176

2.  Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study.

Authors:  V V Kakkar; W J Murray
Journal:  Br J Surg       Date:  1985-10       Impact factor: 6.939

3.  A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter
Journal:  N Engl J Med       Date:  1995-06-22       Impact factor: 91.245

4.  Heparin kinetics in venous thrombosis and pulmonary embolism.

Authors:  J Hirsh; W G van Aken; A S Gallus; C T Dollery; J F Cade; W L Yung
Journal:  Circulation       Date:  1976-04       Impact factor: 29.690

5.  A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.

Authors:  A G Turpie; M N Levine; J Hirsh; C J Carter; R M Jay; P J Powers; M Andrew; R D Hull; M Gent
Journal:  N Engl J Med       Date:  1986-10-09       Impact factor: 91.245

6.  Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis.

Authors:  M T Nurmohamed; F R Rosendaal; H R Büller; E Dekker; D W Hommes; J P Vandenbroucke; E Briët
Journal:  Lancet       Date:  1992-07-18       Impact factor: 79.321

7.  Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

Authors:  H N Magnani
Journal:  Thromb Haemost       Date:  1993-10-18       Impact factor: 5.249

8.  Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis.

Authors:  M V Huisman; H R Büller; J W ten Cate; E A van Royen; J Vreeken; M J Kersten; B Bakx
Journal:  Chest       Date:  1989-03       Impact factor: 9.410

9.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

10.  Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.

Authors:  J S Ginsberg; M T Nurmohamed; M Gent; B MacKinnon; J Sicurella; P Brill-Edwards; M N Levine; A A Panju; P Powers; P Stevens
Journal:  Circulation       Date:  1994-11       Impact factor: 29.690

View more
  4 in total

Review 1.  Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  R Davis; D Faulds
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 2.  Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations.

Authors:  M T Nurmohamed; H ten Cate; J W ten Cate
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

Review 3.  Rational antithrombotic therapy and prophylaxis in elderly, immobile patients.

Authors:  E C van Gorp; D P Brandjes; J W ten Cate
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 4.271

4.  Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.

Authors:  George Dranitsaris; Lesley G Shane; Seth Woodruff
Journal:  J Oncol Pharm Pract       Date:  2017-08-31       Impact factor: 1.809

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.